Drug Trial Radar · NCT01179828
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
Last checked: Nov 19, 2026Latest source record: Apr 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jul 2010
Primary completion
Apr 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Insel Gruppe AG, University Hospital BernAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Bern; University of Zurich; Aalborg University
- First posted
- Aug 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.
Conditions
- Low Back Pain
Interventions
Oxycodone 15mgDrug
15mg single administration p.o.
ClobazamDrug
20mg single administration p.o.
ImipramineDrug
75mg single administration p.o.
TolterodineDrug
1 mg single administration p.o.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in NRS(pain scale) between measurement after and before drug administrationTime frame: 07/2012
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andreas Siegenthaler
Dep. of Anesthesiolgy and Pain Therapy, Bern University Hospital, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.